With HeartMate II, Thoratec has advanced LVAD technology
into the realm of mainstream clinical therapy.
HeartMate II is the most widely used, most extensively studied, most proven and trusted LVAD—providing a powerful treatment option to clinicians and hope to thousands of patients.
Thoratec’s dedication to rigorous clinical evaluation has yielded more clinical evidence supporting HeartMate II than any previous LVAD—with published clinical results demonstrating substantial improvements in survival and quality of life for hundreds of patients, and with ongoing patient follow-up continuing for five years.
- Implanted in more than 7,000 patients*
- Supported over 800 patients for 2+ years and over 90 patients for 4+ years*
- Extensively studied and featured in over 120 peer-reviewed articles, including The New England Journal of Medicine and Journal of American College of Cardiology*
- Consistently strong clinical outcomes in challenging BTT and DT patient populations1, 2, 3
- Lowest published anticoagulation regimen
- Lowest reported stroke rate
- Lowest reported rate of pump thrombosis
- Lowest reported rate of pump exchanges
1 Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1–39.
2 Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anticoagulation. J Heart Lung Transplant. 2009;28:881–7.
3 Slaughter MS, Yoshifumi N, John R, et al. Postoperative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant. 2010;29:616–24.
* As of March 2011